Canagliflozin Ameliorates Myocardial Fibrosis and Cardiac Function in Chronic Heart Failure: A Dose‐Independent Therapeutic Approach
Canagliflozin lindert myokardiale Fibrose und Herzfunktion bei chronischer Herzinsuffizienz: dosisunabhängiger Therapieansatz
Journal of Cellular and Molecular Medicine · 2025-08 · 29 (15)
DOI: 10.1111/jcmm.70718 ↗Auf einen Blick
In einem Rattenmodell der chronischen Herzinsuffizienz verbesserte Canagliflozin die Herzfunktion und verringerte myokardiale Fibrose. Ein Vorteil der hohen gegenüber der niedrigen Dosis zeigte sich nicht.
Fragestellung
Verbessert Canagliflozin bei chronischer Herzinsuffizienz die myokardiale Fibrose und die Herzfunktion, und ist die Wirkung dosisabhängig?
Methode
Rattenmodell mit Isoproterenol über 10 Tage; danach Randomisierung in 5 Gruppen. Canagliflozin 1-mal täglich über 4 Wochen per Magensonde; Vergleich mit Enalapril.
Ergebnisse
Canagliflozin verbesserte echokardiographische Parameter, senkte NT-pro-BNP und reduzierte Kollagenablagerung sowie Fibrosemarker. RNA-Sequenzierung und qRT-PCR zeigten Veränderungen in Fibrose-assoziierten Genen.
Schlussfolgerung der Autor:innen
Canagliflozin konnte die myokardiale Fibrose direkt verbessern und so die Progression der chronischen Herzinsuffizienz kontrollieren. Die Wirkung war möglicherweise nicht dosisabhängig.
Kernaussagen
- Herzfunktion und Fibrose verbesserten sich unter Canagliflozin
- NT-pro-BNP und Fibrosemarker wurden reduziert
- Keine bessere Wirkung der hohen im Vergleich zur niedrigen Dosis
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 10.08.2025. Verfasst von Haomiao Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospi…. Hauptthemen laut MEDLINE: Heart Failure, Myocardium, Canagliflozin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China, Jinan City Clinical Medicine Science and Technology Innovation Plan.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The myocardial fibrosis leading to cardiac remodelling is a key factor in the progression of chronic heart failure. The present study aims to investigate the mechanism of canagliflozin's improvement of cardiac fibrosis in chronic heart failure rats and the effect of dose on efficacy. Chronic heart failure models were established by intraperitoneal injection of isoproterenol to rats for 10 days. The rats were then randomised into five groups: control rats, chronic heart failure rats, rats treated with a low dose of canagliflozin, rats treated with a high dose of canagliflozin and rats treated with enalapril. Canagliflozin was administered once daily for 4 weeks by gastric feeding. The rats were then euthanised after cardiac function analysis by echocardiography. Detection of chronic heart failure markers from serum was performed using enzyme‐linked immunosorbent assay kits. The tissue sections were examined by histological staining to assess the cardioprotective effect of canagliflozin in chronic heart failure rats. Myocardial interstitial fibrosis was evaluated by specific immunostaining. The control, chronic heart failure and low dose of canagliflozin groups were sequenced and analysed to identify differentially expressed genes, and the expression of selected genes was verified by qRT‐PCR. Echocardiographic measurements provided evidence supporting the ability of canagliflozin to improve cardiac function. Canagliflozin treatment reduced the chronic heart failure marker N‐terminal pro‐B‐type natriuretic peptide. HE staining and Masson's trichrome staining demonstrated that canagliflozin effectively reduced collagen deposition and alleviated myocardial fibrosis. The immunohistochemical staining revealed that treatment with canagliflozin inhibited the expression of fibrosis markers Collagen I, Collagen III and fibronectin 1. The differentially expressed genes identified through RNA sequencing were found to be enriched in the ECM–receptor interaction pathway. The results of qRT‐PCR demonstrated that canagliflozin reduced the level of differentially expressed genes involving collagen type I alpha 1 chain, collagen type I alpha 2 chain, collagen type III alpha 1 chain and fibronectin 1. Interestingly, the results did not show a trend toward better efficacy of high‐dose compared with low‐dose canagliflozin in the treatment of chronic heart failure. In summary, canagliflozin could directly improve myocardial fibrosis to control the progression of chronic heart failure. Canagliflozin may not be dose‐dependent in the treatment of chronic heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
- Department of Endocrinology and Metabology, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China.
- Children's Hospital Affiliated to Shandong University & Jinan Children's Hospital, Jinan, China.
- Cheeloo College of Medicine, Shandong University, Jinan, China.
- College of Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
ORCID-Profile: Zhenzhong Han, Zhongwen Zhang
Förderung
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
- Jinan City Clinical Medicine Science and Technology Innovation Plan
Zitieren
APA
Yu, H., Han, Z., Chang, W., Zhou, H., Du, B., Jia, B., Fu, H., Yin, Y., Kan, M., Yu, S., & Zhang, Z. (2025). Canagliflozin Ameliorates Myocardial Fibrosis and Cardiac Function in Chronic Heart Failure: A Dose‐Independent Therapeutic Approach. Journal of Cellular and Molecular Medicine, 29(15). https://doi.org/10.1111/jcmm.70718
Vancouver
Yu H, Han Z, Chang W, Zhou H, Du B, Jia B, et al. Canagliflozin Ameliorates Myocardial Fibrosis and Cardiac Function in Chronic Heart Failure: A Dose‐Independent Therapeutic Approach. Journal of Cellular and Molecular Medicine. 2025;29(15). doi:10.1111/jcmm.70718
BibTeX
@article{Yu2025,
author = {Yu, Haomiao and Han, Zhenzhong and Chang, Wanpeng and Zhou, Huiming and Du, Bingyu and Jia, Baoxue and Fu, Hui and Yin, Yanyan and Kan, Mengfan and Yu, Shaohong and Zhang, Zhongwen},
title = {Canagliflozin Ameliorates Myocardial Fibrosis and Cardiac Function in Chronic Heart Failure: A Dose‐Independent Therapeutic Approach},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
volume = {29},
number = {15},
doi = {10.1111/jcmm.70718}
}
EUVIMED